The CMF regimen as an adjuvant therapy for breast cancer with axillary node involvement has become « standard therapy » at least for some subsets of patients (according to the Second Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer). The acute toxicity of such a regimen Is usually mild and well tolerated; the late toxicity is mainly represented by amenorrhea. Here a case of acute non-lym-phoid-leukemia (ANLL) after six CMF cycles is reported.
Get full access to this article
View all access options for this article.
References
1.
BonadonnaG., ValagussaP.: Current status of adjuvant chemotherapy for breast cancer.Semin. Oncol., 14-1: 8–22, 1987.
2.
BuzdarA.U., HortobagyG.N., MarcusC.E., BlumenscheinG., MontagueE.D.: Results of adjuvant chemotherapy trials in breast cancer at M.D. Anderson Hospital and Tumor Institute.Natl. Cancer Inst. Monogr., 1: 81–85, 1986.
3.
ColemanN.C., WilliamsC.J., FlintA., GlatsteinE.J., Ro-sembergS.A., KaplanH.S.: Hematologic neoplasia in patients treated for Hodgkin's disease.N. Engl. J. Med., 297: 1249–1252, 1977.
4.
Consensus Conference: Adjuvant chemotherapy for breast cancer.JAMA, 254: 3461–3463, 1985.
5.
FisherB., RocketteH., FisherE.R., SassR.: Leukemia in breast cancer patient following adjuvant chemotherapy or postoperative radiotherapy: the NSABP experience.J. Clin. Oncol., 3: 1640–1658, 1985.
6.
Pedersen-BjergaardJ., LarsenS.O.: Incidence of acute non lymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.N. Engl. J. Med., 307: 965–971, 1982.
